SH2D2A

Across TCGA pan-cancer cohorts, SH2D2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH2D2A data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SH2D2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SH2D2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where SH2D2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.865	0.406	<.001	41	view →
PDAC	OS	Median	All	1.000	0.213	.024	20	view →
HNSC	DFS	Median	III,IV	0.364	0.716	.007	19	view →
LSCC	OS	Quartile	III,IV	0.458	0.989	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH2D2A–LUAD (DFS)

Open the LUAD breakdown →